scholarly journals Rare Coagulation Disorders

1999 ◽  
Vol 82 (10) ◽  
pp. 1207-1214 ◽  
Author(s):  
Flora Peyvandi ◽  
P. M. Mannucci

SummaryThe type of hemorrhagic manifestations that occur in patients with recessively transmitted coagulation disorders and their optimal treatment are not well established as for hemophilia A and B and von Willebrand disease, due to the rarity of these disorders. In a Muslim country like Iran where consanguineous marriages are frequent these disorders are less rare. We chose to evaluate the pattern of bleeding symptoms in 237 Iranian patients with the inherited deficiencies of fibrinogen, factor II, combined factor V and factor VIII, factor V, factor VII and factor X. Considering “severe” life-endangering hemorrhages such as those in the CNS, gastrointestinal tract and from the umbilical cord and those potentially handicapping such as hematomas and hemarthroses; and “mild” epistaxis, menorrhagia, hematuria, oral and postsurgical bleeding, it would appear the most severe diseases are factor X and factor II deficiencies. For the remaining defects only a minority of patients, even those with unmeasurable plasma levels, had life-endangering hemorrhages or muscoloskeletal disabilities as a consequence of hemarthroses and hematomas. The relatively mild severity of clinical manifestations in recessive coagulation disorders commands safety as the primary criterion in the choice of replacement material for treatment. Hence, virally inactivated plasma and factor concentrates should be the products of choice.

1987 ◽  
Author(s):  
A Blanco ◽  
R Bonfil ◽  
O Bustoabad ◽  
M Lazzari

Increased deposition and lysis of fibrin, associated with malignant tissue, has led to look for activators of both the coagulation and fibrinolytic systems produced by tumor cells. We report the evidences of a procoagblant activity (PA) in the extracts of intratumoral necrosis from two experimental breast adenocarcinomas in murine model (BALB/c). The tumors have different metastatic capacity (MC). M3 without MC and MM3 with high MC.The addition of the extracts to: 1- Normal Plasma, 2- Deficient substrates in coagulation factors, 3- Purified, fibrinogen (I), showed: 1- Shortening of the plasma recalcification time (PRT) and APTT, without ;modification on prothrombin time (PT), 2- Reduction of the PRT on deficient substrates in factors: VIII; VII; VII and X; V; V, VII and X; without modification on II deficient substrate, 3- No PA on I. Table:C: Control, s: seconds, m: minutes. The PA was not affected by heparin. The results suggest that the PA is independent of the presence of either factor VIII or factor VII (intrinsic or extrinsic pathway respectively), as well as presence of either factor V or factor X. Any effect was observed either on factor II deficient substrate or on I, so, there was no evidence of thrombin activity The PA could be act directly on factor II, suggesting that fibrin formation could be induced by a “non-classical” activation pathway. No significant differences (p>0.5) in PA were observed between both tumoral necrosis extracts. The necrotic area in M3 (37%) is bigger than in MM3 (18%). So, much more PA could be present in MM3 and this could play a role in the MC of this tumor.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4788-4788
Author(s):  
Nataliya Melnyk ◽  
Jonathan Harrison

Background Acquired coagulopathies are a common problem in Hematology, and are most often due either to medication effect, liver disease, or consumption. Among the uncommon causes of acquired coagulopathy, inhibitory auto-antibodies may develop, either in the setting of autoimmune diseases, in the setting of lymphoproliferative disorders, or as isolated inhibitory immunoglobulins. Uncommonly, the adsorption of coagulation factors from the circulation into the tissues by extracellular deposition of pathologic amyloid results in an acquired factor deficiency, due to clearance of factor from the circulation that exceeds the body's ability to produce factor. When amyoidosis does cause a coagulapathy, it is most often the result of the adsorption of Factor X by the amyloid protein, resulting in an acquired Factor X deficiency. However, there are rare reports of amyloidosis being associated with other factor deficiencies. We report a case of amyloidosis that was associated with a severe bleeding diathesis, with the etiology of the bleeding disorder being due to both acquired Factor V deficiency and concomitant acquired von Willebrand Disease. Case Report A previously healthy 51-year-old gentleman presented to an outside medical center for evaluation and management of recurrent bleeding episodes. The patient had a prior medical history significant only for right ankle trauma in the year 2005, following which he underwent a total of 4 surgical procedures; there was no excessive bleeding complicating the patient's surgeries. He was then in his usual state of health until September, 2012 when he developed onset of severe abdominal pain and was admitted to the outside facility. Following hospitalization for several months at the outside facility, he was admitted to our institution. Physical examination was remarkable for extensive ecchymoses, and for splenomegaly to 18 cm. span by exam, confirmed by imaging. CT scan showed multiple peri-caval and periaortic nodes present up to 1.7 cm in size, with shotty inguinal lymph nodes. A complete blood count showed White blood count 21,600, hemoglobin 8.0 g/dL, hematocrit 24%, platelet count 370,000, Hepatic function studies and renal function studies, as well as electrolytes, were normal on admission. Coagulation studies revealed Prothrombin Time prolonged at 16.8 seconds (normal < 12.7), aPTT prolonged at 44. Mixing patient plasma with equal volume normal plasma corrected both the PT and aPTT. Detailed factor assays showed markedly decreased Factor V activity of 27%; Ristocetin Cofactor activity was markedly decreased at 49%, but von Willebrand antigen was elevated at 213%. Multimer analysis was consistent with Type II vWD (see figure 1). The patient received fresh frozen plasma and Humate P, with transient correction of the bleeding diathesis. This permitted inguinal lymph node biopsy, which documented AL amyloidosis. Extraction of the protein from the lymph node documented AL lambda light chain amyloid (see figure 2). Marrow biopsy documented IgG lambda multiple myeloma. The patient was treated using Bortezumib plus Dexamethasone, and achieved a complete remission, with normalization of the coagulation parameters and factor levels over the following several months. His bleeding diathesis has fully resolved, and Karnofsky performance status improved to 100%. Conclusion Although there are several case reports of acquired von Willebrand disease on the basis of amyloidosis, and several case reports of acquired Factor V deficiency on the basis of amyloidosis, this appears to be the first reported case of both acquired vWD and acquired Factor V deficiency on the basis of amyloidosis. Disclosures: No relevant conflicts of interest to declare.


2003 ◽  
Vol 90 (12) ◽  
pp. 1094-1099 ◽  
Author(s):  
Daniela Berger ◽  
Heinrich Mattle ◽  
Bernhard Lämmle ◽  
Walter Wuillemin ◽  
Franziska Demarmels Biasiutti

SummaryThe role played by hemostasis in the pathogenesis of ischemic stroke is still controversial. In the present study, we looked for a possible association of ischemic stroke and high clotting activity of factor II (FII:C), factor V (FV:C), factor VII (FVII:C), factor X (FX:C) and fibrinogen. We investigated 157 non-anti-coagulated patients (86 males, 71 females; median age 41 y, range 16-73 ), who had survived ischemic stroke for at least 2 months, and 193 healthy controls with similar age and sex distribution (104 males, 89 females; median age 39 y, range 19-74). Patients showed significantly higher body mass index, as well as significantly higher prevalence of arterial hypertension, smoking and hyperlipidemia. FV:C (p = 0.05), FX:C (p = 0.04) and fibrinogen (p = 0.05) were higher in patients as compared to controls. In a univariate risk analysis FX:C and FV:C were associated with the relative risk for ischemic stroke showing an odds ratio (OR) of up to 2.8 (95% CI: 1.05-7.6) and 3.4 (95%CI: 1.4-7.9), respectively, for levels above 130%. In a multivariate analysis using a logistic regression model including age, sex, arterial hypertension, smoking habit, diabetes, hyperlipidemia, BMI and the coagulation factors, FV:C was still found to significantly (p=0.03) add to the risk of ischemic stroke. An increase of factor FV:C by 10% was associated with an increase in the relative risk of 19% (95% CI.: 2%-38%). In conclusion, we found a high plasma level of FV:C to be a prevalent (FV:C > 130% in 20/157 patients) and independent risk factor for ischemic stroke.


ILAR Journal ◽  
2009 ◽  
Vol 50 (2) ◽  
pp. 144-167 ◽  
Author(s):  
T. C. Nichols ◽  
A. M. Dillow ◽  
H. W. G. Franck ◽  
E. P. Merricks ◽  
R. A. Raymer ◽  
...  

2019 ◽  
Vol 64 (4) ◽  
pp. 489-503
Author(s):  
E. V. Yakovleva ◽  
N. I. Konyashina ◽  
L. A. Gorgidze ◽  
V. L. Surin ◽  
O. S. Pshenichnikova ◽  
...  

Introduction. Haemophilia and von Willebrand disease constitute the most common hereditary coagulopathies. However, such rare hereditary coagulopathies as congenital factor V defi ciency can mistakingly be referred to these diseases.Aim. To describe the clinical manifestations and treatment of congenital factor V defi ciency.General findings. The article presents a literature review, as well as three case studies of patients with congenital factor V deficiency. Given that the choice of haemostatic therapy depends on accurate diagnosis, issues associated with the differential diagnosis of hereditary coagulopathies are considered as well. Patients with congenital factor V deficiency require continuous monitoring by a haematologist in order to control spontaneous or induced haemorrhagic syndrome, as well as to plan haemostatic therapy in case of surgical procedures, pregnancy or childbirth.Conflict of interest: the authors declare no conflict of interest.Financial disclosure: the study had no sponsorship.


2009 ◽  
Vol 101 (06) ◽  
pp. 1104-1111 ◽  
Author(s):  
Claudia Chi ◽  
Christine Lee ◽  
Adrian England ◽  
Jaishree Hingorani ◽  
James Paintsil ◽  
...  

SummaryA retrospective review was carried out on the methods of obstetric analgesia/anesthesia used in 80 pregnancies amongst 63 women with inherited bleeding disorders (19 factor XI deficiency, 16 carriers of haemophilia, 15 von Willebrand disease, seven platelet function disorders, four factor VII deficiency, one factor VII and XI deficiency and one factor X deficiency). In 72 pregnancies, the woman was seen antenatally in a multidisciplinary clinic to discuss and plan pain relief options. Regional block was performed for 41 pregnancies. The mothers were known to have a bleeding disorder in 35 of these pregnancies. Prophylactic cover was given in 10 pregnancies prior to the insertion of regional block but not required in the remaining 25 pregnancies because the coagulation defects had spontaneously normalised at term. There were six reported adverse effects from regional block similar to that found in the general population: inadequate anesthesia/analgesia (2), bloody tap (2), hypotension and a possible dural puncture which was treated conservatively. There were no reports of long-term complications. The findings show that it is possible to offer women with inherited bleeding disorders the option of regional block provided their coagulation defects have normalised, either spontaneously during pregnancy or following adequate haemostatic cover.


Author(s):  
Д.Б. Флоринский ◽  
А.В. Пшонкин ◽  
А.В. Полетаев ◽  
Д.В. Федорова ◽  
Е.А. Серегина ◽  
...  

Введение. Редкие коагулопатии представляют собой гетерогенную группу наследственных заболеваний, для которых характерен количественный или качественный дефицит факторов свертывания крови. Цель исследования: проанализировать частоту встречаемости и клинические проявления редких коагулопатий у детей, определить корреляции степени тяжести клинических проявлений с активностью дефицитного фактора. Материалы и методы. На основании анализа деперсонифицированной базы данных из общего числа визитов к врачам, специализирующимся на болезнях свертывающей системы, с января 2017 г. по декабрь 2019 г. была изучена частота встречаемости редких коагулопатий. Оценивали основные локализации кровотечений и степень выраженности клинических проявлений, используя шкалу педиатрического опросника кровоточивости (англ. Pediatric Bleeding Questionnaire, PBQ). Анализ корреляции между величиной PBQ и значением активности дефицитного фактора проводили с применением метода Пирсона. Результаты. За 2017–2019 гг. в ФГБУ НМИЦ ДГОИ им. Д. Рогачева Минздрава России диагностировано 47 пациентов с редкими коагулопатиями: 14 пациентов с гипо/афибриногенемией, 21 пациент с дефицитом фактора VII, 5 пациентов с дефицитом фактора XI, 3 пациента с комбинированным дефицитом витамин К-зависимых факторов, 2 пациента с дефицитом фактора V, 1 пациент с дефицитом фактора X и 1 пациент с сочетанным дефицитом факторов V и VIII. Заключение. Распространенность той или иной редкой коагулопатии подвержена этническим особенностям населения и не всегда пропорциональна ожидаемой частоте. Требуется больше данных для установления местных особенностей распространения редких коагулопатий и выработки адекватных критериев диагностики. Background. Rare bleeding disorders are a heterogeneous group of hereditary diseases characterized by a quantitative or qualitative deficiency of blood coagulation factors. Objectives: to analyze the incidence and clinical manifestations of various rare bleeding disorders in children, to identify correlations of clinical manifestations severity with the activity of a deficient factor. Patients/Methods. According depersonalized database of the total number of visits (from January 2017 to December 2019) to doctors specializing in diseases of the coagulation system, the incidence of rare bleeding disorders was studied. The main sites of bleeding and the severity of clinical manifestations were assessed with the Pediatric Bleeding Questionnaire (PBQ) scale. Pearson method was used to analyze the correlation between the PBQ value and the deficient factor activity. Results. For years 2017–2019 at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology 47 patients with rare bleeding disorders were diagnosed, оf these, 14 patients with hypo/afibrinogenemia, 21 patients with factor VII deficiency, 5 patients with factor XI deficiency, 3 patients with combined deficiency of vitamin K-dependent factors, 2 patients with factor V deficiency, 1 patient with factor X deficiency and 1 patient with combined factors V and VIII deficiency. Conclusions. The prevalence of one or another rare bleeding disorder is vulnerable to ethnic characteristics of the population and is not always proportional to the expected frequency. More data is required to establish the local characteristics of the spread of rare bleeding disorders and to develop adequate diagnostic criteria.


1974 ◽  
Vol 32 (01) ◽  
pp. 057-064 ◽  
Author(s):  
Y Nemerson ◽  
S.A Silverberg ◽  
J Jesty

SummaryTwo reactions of the extrinsic pathway of coagulation, the activations of Factor X and prothrombin, have been studied in purified systems and shown to be self-damping. Factor X was activated by the tissue factor - Factor VII complex, and prothrombin by two systems: the coagulant protein of Taipan venom, and the physiological complex of activated Factor X, Factor V, lipid, and calcium ions. In each case the yield of enzyme, activated Factor X or thrombin, is a function of the concentration of activator. These and other observations are considered as a basis for a control mechanism in coagulation.


1970 ◽  
Vol 23 (03) ◽  
pp. 593-600
Author(s):  
P Pudlák ◽  
I Farská ◽  
V Brabec ◽  
V Pospíšilová

Summary1. The following coagulation changes were found in rats with experimental hypersplenism: a mild prolongation of the recalcification time, shortened times in Quick’s test, a lowered activity in plasma thrombin time and shortened times in the partial thromboplastin test. Concentrations of factor II, V, VII (+X), VIII and X did not differ from those of normal control rats.2. The administration of adrenaline to hypersplenic rats induced the correction of the partial thromboplastin test, Quick’s test and plasma thrombin time to normal values. Concentrations of coagulation factors were not significantly changed. An increase was found in factor V.3. Splenectomy performed in hypersplenic rats was followed by a shortened recalcification time, a prolongation of the partial thromboplastin test and of the test with partial thromboplastin and kaolin. A prolongation was also observed in Quick’s test. Complete correction of plasma thrombin time was not observed. The concentration of factor VII increased.4. The administration of adrenaline to splenectomized rats with experimental hypersplenism did not induce any significant changes with the exception of a corrected plasma thrombin time and a decreased concentration of factor VIII.5. A different reaction of factor VIII to adrenaline in normal and hypersplenic rats is pointed out.


Sign in / Sign up

Export Citation Format

Share Document